Langerhan s ' cell histiocytosis (LCH)-once called histiocyto sis X-is a complex reticuloendothelial disease that of ten involves the head and neck. We discuss the current nomenclature ofthis disease and review its pathologic and clinical characteristics, with part icular emphasis on the role of the head and neck surgeon. LCH can be challenging to diagnose, and the otolaryngologist must be f amiliar with its varied presentations. Because LCH usually responds well to medical therapy and extensive resection can easily cause more morbidity than the disease itself, a minimalist approach to treatment usually p rovides the best outcome. We also discuss the case ofa 9-month-old girl with LCH who presented with aggressive head and neck disease.
Introduction
Like cancer, Langerhan s' cell histiocyt osis (LCH) can affect any organ system, and it can be prog ressive and fatal. In other cases, LCH is locali zed and self-limited. In most cases, LCH resolve s with medic al treatment, but the diagn osis cannot be made without anal ysis of a tissue sample, which is usually obtained by a surgeon or dermatologist. The disease is rare, but when it does occur, it often does so in the head and neck . The otolaryngologist should be famili ar with the varied presentations of this disease and und erstand that it often masquerades as more common head and neck diseases. The head and neck surgeon ther efore plays a critical role in the diagnosis of LCH and in following the patient once the diagno sis has been established.
In this articl e, we describ e the case of a 9-month-old girl with undiagnosed LCH who had been referred to us by the emergency department for evaluation of an oral mass. We also discuss the current nomenclature of the disea se and review its pathologic and clinic al characteristics, with particular emph asis on head and neck involvement. Finally, we addre ss new advances in treatment, and we present our philo sophy on the role of the head and neck surgeon.
Case report
A mother brought her 9-month-old daughter to the emergency department for evaluation of an oral mass that had been growing for 2 weeks. The mother had first noticed the mass while her daughte r was brea st-feeding. She also noticed that the infant had not been feeding as much as usual. Otherwise, the child had been sleeping, crying, and developi ng normally. The infant' s medical history was significant for a 4-month period of bilateral otitis externa, and she was respondin g minim ally to neomycin/polymyxin B/hydrocortisone otic drop s that had been prescribed by her prim ary care phy sician . The patient also had persistent scalp and diaper rashes that were not responding to over-the-counter cream s. The remainder of the child's medic al history was unremarkable.
On physical examination, the infant was well nourished . She had a robu st cry and interacted normally. Her head and neck examination was notable for an eczem atous scalp rash that involved the conchae of both ears. Her external auditory canals were edem atou s, and there was scant yellowish oto rrhea bilaterally. Her tympanic membrane s were intact. An exophytic, spongy, light-brown , palatal mass, approximately 3 x I em in size, extended from the midl ine anteriorly along the left lateral aspect of the hard pal ate. A second lesion, I x 1.5 em in size, was noted on the right lateral palate. The nasopharynx was normal. The rem ainder of the physical examination was norm al except for the severe eczematous diaper rash and the similar rash on the scalp. The complete blood count and chemis try panels were normal, as was a chest x-ray . Computed tom ography (CT) showe d that the palatal mass involved the maxilla ry sinus and approached, but did not involve, the orbit (fig ure I).
We took the patient to the operating room and obtained a biopsy of the palatal mass. Pathologic analysis led to a diagnosis of LCH (fig ure 2). A derm atologist obtained a biopsy of the groi n ras h, and the diagnosis was the same. The patie nt was referred to the hematology department, and she was started on weekly vinblastine and prednisolone. Hydrocortisone crea m was prescribed for the ras h, and the patient was kept on neomycin/ polymyxin B/ hyd rocortisone ear dro ps for her otitis exte rna.
The palatal mass resolved rapidly and the otitis externa responded, as well. However, the ras h recurred follow ing the comp letion of therap y, so the patient resumed the same chemotherapeu tic medica tions for 3 month s. Topical steroid therapy kep t the rash under reasonable co ntrol, and at follow-up, the patient was doing well and deve loping normally.
Discussion
Lichtenstein origi nated the term histiocy tosis X in 1953 to describe a group of poorly understood diseases that di ffered in present ation but had a co mmo n pathologic characteristic: histio cyte prolifera tion. I At that time, histiocytosis X was subdiv ided into three types: (I) eosi nophilic granuloma, an isolated osteo lyt ic lesion; (2) Hand-Schull er-Christian disease, a multifocal version of eosinophilic gran uloma that is ofte n accompanied by systemic manifestations; and (3) Letterer-Siwe disease, a syste mic, rapidly prog ress ive for m of histiocytosis X.
Seve ral decades passe d before a specific type of histiocyte-the Langerh ans' cell-was identified as the culprit.2-5 In 1987, the international Histiocyte Society changed the name of the disease from histiocytosis X to Langerhans ' cell histiocytosis." Authors of reports in the otolary ngo logy literatur e have bee n slow to adop t this new terminology, and many still refer to LCH by its former name.
Pathology. Strict diagnostic cri teria have been published by the Histiocyte Society." Fres h-tissue biopsy is required to diagnose the disease. In order to establis h a definit ive diagnosis, either Birb eck' s gra nules must be ident ified on electron microscop y or the cells must be CD 1a-pos itive. A less certain diagnosis can be made if biopsy reveals charac teristic morph ology and if two or more of the following are prese nt on staining: charac teristic peanut lectin binding, S-l 00 protein, alpha -D-mannosidase, and adenosine triphosphatase. A weaker presumptive diagnosis ca n be made if histologic characteris tics are consistent wit h those reported in the literature.
Although the precise pathoge nes is of LCH is unknown, Egeler et al have reported important information rega rding the disease process.' Beca use Langerh ans' cells are 342 Figure 1 . CT shows that the palatal mass involves the maxillary sinus and approaches the orbit.
the only monoclonal cells in LCH, Egeler et al spec ulated that LCH is a type of neoplastic phenomenon. Therefore, the under lying cause of the disease may be a genetic defec t, an abnormal response to infection, an autoimmune quirk, or a com bination of these factors.
A histiocyte is an antige n-prese nting immune cell that originates in the bone marro w and evo lves into one of two cell types: macrophage or dendrite. Health y Langerhans' cells circulate thro ugh the epidermis, lungs, and the vagi--nal and orob uccal epithelia seeki ng foreign antige ns.S The dendritic nature of these cells may enhance the ir abi lity to capture and transport antigens (figure 3) .9 Both norma l and diseased Langerhans' cells are CD Ia-and S-100 protein-positive. T hey also con tain Birbeck's gra nules, which are pentala minar cytop lasmic incl usion bod ies that sometimes have a dilated termin al (" tennis racquet" appearance). Under normal circ umstances, Langerhans' ce lls enter the lymphatic system and trave l to the T-ce ll areas of the spleen and drai ning lymp h nodes . Once there, these cellsnow called interdig itating dendritic cells-present antigen to the T ce lls." A bidirectional release of cytokines like ly ens ues as part of the imm une response.' In the diseased state, Langerhans' histiocytes lose their healthy dend ritic morphology and beco me less-capable round ce lls. These cells barely rese mble their for mer manifestation as they assume a more macropha gic appearance, with www.optomic.com mail@optomic.com
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· Straight or inclined stereoscopic binocular head. vesicular nuclei and abundant, often vacuolated cytoplasm.'? Angeli et al have noted that as LCH progresses, many of the diseased Langerhans' cell s are replaced by fibrosis. 11 On routine pathologic staining, the "burned out" appearance of these diseased cells can lead the pathologist to confuse LCH with such conditions as osteomyelitis.
Egeler et al examined multiple LCH tissue specimens with antibody-based immunohistochemistry and doublestaining techniques." They concluded that in the diseased state , the norm al production of cytokines by Langerhans ' cells and CD3+ T cells becomes uncontrolled. They also noted that eosinophils produce cytokines in some lesions. In that study, cytokines were abundant in all of the specimens, regardless of the patient's age, sex, or lesion site. Furthermore, the site of the lesion did not significantly affect its histologic appearance, a finding that was consistent with those of others.7.11, 12 Egeler et al proposed that the cytokine storm produced by the combined effort of T cell s and LCH cells allows the LCH lesion to grow and mature." Systemic symptoms of LCH such as fever may also be the result of cytokine activity. In addition , several of the cytokines they identified are known to promote nec rosis, fibro sis, and bone resorption-all of which are typical of LCH lesions. Like cancer, LCH can affect almost any organ system . Its systemic manifestations include weight loss, fever , chill s, and fatigue. The seborrheic, scaly , erythematous rash seen in our patient was a typical presentation .
When LCH involves the orbital wall, proptosis may be the presenting sign. LCH that affects the mastoid can mimic mastoiditis. Mandibular disease may lead to fractures, "floating teeth, " gingivitis, or localized soft-tissue swelling. When LCH affects the endocrine system, the most common presentation is diabetes insipidus. When the anterior pituitary gland is involved, the production of , growth hormone may drop , Central nervous system (CNS) involvement usually occurs late in the disease process. Dysarthria, dysphagia, ataxia , nyst agmus, and cranial nerve symptoms indicate CNS involvement.
Disease course. The course ofLCH is unpredictable. In some cases, it resolves without treatment. On the other hand , it can recur even after the initial response to treatment was successful. A chronic intermittent course is sometimes see n before the disease resol ves. T herefore, follow-up into ea rly adulthood is import an t for all children with LCH. Monthly visi ts for I year fo llowed by annual visits therea fter are usually adequate."
Sites ofdisease. LCH is sometimes limit ed to a single site, whi le in other cases it invo lves mul tiple sites and organ systems. Patient s with isolated lesion s fare better. Solitary lesion s most ofte n affect the skin, bone, or a lymph node. LCH is considere d to be dissem inat ed whe n two or more organ systems are involve d. Th e head and neck is freque ntly invo lved in LCH; one study showed that 87 % of pati ent s had disease in this region ."
Patient s with disseminated disease tend to be younge r. Th e systemic , progressive form of the disease usuall y arises in children younger than 2 years, while the more ben ign isolated bon e lesions usu all y affec t children between the ages of 5 and 15 yea rs." Di sease that causes org an failure is associated with a poorer outcome; almos t all of the 10% of LCH patient s who die from th is disease experience organ failure of one typ e or anot her.
Laboratory tests must be perform ed to help determin e if orga ns such as the liver or bone marrow are involved. Th e choice of tests and procedures pe rformed duri ng the initial work-up depend s on where the lesion is locat ed . For exa mple, if the patient has pulmonary symptoms, bron choalveolar lavage sho uld be performed. Wh en gastrointestinal inv olv em ent is suspec ted, biopsies should be taken. When it appears that the patie nt has diabetes insipidus ste mm ing fro m pituit ary involvem ent, a waterdepri vation test may be indicated.
Classification ofdisease. Alessi and Maceri rev iewed the cases of 28 children (age range: bir th to 16 yr) wh o were treated fo r head and neck LCH at Children ' s Hospital of Los Ange les and devi sed a straightforward classifica tion system for LCH I7:
• Patient s with type 1 (benig n) d isease were usually treated with curett age alone, and they did ver y well. Clear margin s were not a prim ary surgical goal.
• Patient s with type 2 (inter med iate) di sease had lesion s at mult iple sites. Th ey requ ired surge ry orradiation therapy, and they tend ed to surv ive , albeit with varyi ng degrees of morb idit y.
• Patient s with type 3 (disseminated) disease were younges t (age range : 2 wk to 2 yr). Bone marrow was usuall y invo lve d. Th ey were treat ed with chem oth erapy, but none surv ived. Alessi and Maceri co ncluded that surgery might have a role in cer tain patient s with di sseminated disease, but only as a palli ative measur e.
An geli et al reviewed a series of 25 cases of head and neck LCH in ch ild ren age d 6 months to 17 years.I I In thi s group, 16 patients had type I disease, 8 had typ e 2 disease, and 1 had type 3 disease:
• Of the 16 patient s who had type 1 di sease, 14 had sku ll involvement and 2 had mandibular invo lve me nt. Cu rettage was the main stay of treatment. In 2 of these patients, 34 6 surgery was lim ited because of orbi tal invol vem ent , so postoperat ive radiation was ad ministered as we ll. All patien ts in th is gro up were disease-free at 11 years of foll ow-up.
• Th e 8 patient s who had type 2 disease witho ut visceral inv olvem ent und er went surge ry whe n possible; otherwise , they were treated with radiatio n or che mo therapy. Most of these patients we re alive with di sease several years after prese ntation.
• Th e patient who had type 3 disease involving vital orga ns was I yea r old at present ation and died of LCH wit hin 1 year.
Irving et al reported a re tros pec tive study of LC H in 131 children age d 5 days to 16 yea rs (ma le to fem ale ratio: 1.7: 1; mean foll ow-u p: 5.2 yr) ." Som e 62 % of these patient s ex hibited head and neck involvem ent at presentati on , and 73% experience d head and neck mani festations during their di sea se co urse . Th e auth ors found that the mo st frequently affected area of the head and neck was the skull vault (48 % of cases), fo llowed by the meatal skin of the externa l auditory ca nal (24%) and the cervical lymph nodes (2 1%). Th e temporal bone was involved in 19 % of cases, the maxilla in 10%, and the mandible in 6%. Th ey found an associ ation between meatal sk in involvement and multi system disease. Th ey also found that 78 % of pati ent s with ce rvical node involvem ent had mult isystem disea se. Som e 95 % of the skull lesion s resolved with treatm ent, regardl ess of whether the pati ent had mul tisys tem disease. A poor outco me was assoc iated with presen tati on at age 2 yea rs or younger, vital organ dysfun cti on, and mul tisystem disease.
In the presen ce of multisystem disease, Irving et al found that head and neck lesions tend ed to resolve very we ll with medic al treatm en t. " Th ey recommend ed a 1month cou rse of predni solone at 2 mg/k g/d ay, follo wed by a 2-mo nth taper. Patient s who fail to imp ro ve on thi s regimen shou ld be give n a co urse of eithe r a vinca alka loid or etopos ide . Of co urse, it is importan t to co nsider the side effects of agg res sive chemo thera py, which include secondary malign ancy, sepsis, azoo spermia, and immunosuppression." .
Watchful waitin g may be the best approach to singlesystem disea se involving the head and neck. In many cases, lesions regress spontaneously without treatm ent .'>" When treatment is necessary, a minim alist ap proach should be selected-one th at includes a topi cal steroid, topical mu stine (nitroge n mu sta rd, an alky lat ing age nt), and possibly steroi d inject ion s. Accord ing to Irving et ai, surgery should be co nsi dere d for treatm en t of head and neck disease only when there is progression despit e medica l treatm ent or whe n delicate struc tures suc h as the optic nerve or spinal co rd are at risk." Wh en surgery is requ ired , it can usu all y be limit ed to cure ttage or polypectom y. Wh en a lesion ca nnot be reached surgica lly-for example, in cases of deep temp oral bone invo lve me nt or when surgery wou ld threa ten vita l structures-radia tion ther apy may be administered. A do se of 550 to 600 cGy is safe, alt hough as mu ch as 1,000 cGy can be given wi thout causing side effect s.P-" Rad iation the rapy has been shown to be effecti ve in treating these lesion s," but it ca n ca use secondary ma lignancy , chronic oti tis med ia," and problems wit h bo ne growth in children. Irvin g et al recommend ed that radi ati on be used only as a last resort. 15 Despite the high rate of head and neck invol vem ent , Irvin g et al noted that LCH lesion s cause relatively littl e morbidity. In their ex pe rience , morbidity rel ated to head and neck di sea se was more likel y to be ca used by aggressive surgery than by the di sease itself. Th eir study spa nned 30 years, and the authors noted a change in their therapeutic approach over time. Initi ally , LCH was con sid ered to be a typ e of malignancy and was therefore treated aggressively. T ow ard the latter part of their study, they came to view the di sease as more akin to a reacti ve proc ess, and it is now treated more co nservative ly at thei r institution. "
Otologic manifestation s. Ot ologic mani festation s have been repo rted to occ ur in 15 to 61% of pati ents wi th LCH.3.24-27Bilateral ear or temporal bo ne involveme nt has occ urre d in as many as 30% of reported ca ses .3.22.27 Althou gh the ea r and tem poral bone are co mmonly affected, the disease is ofte n mo re significant in othe r areas ; as a resu lt, oto log ic LCH may be overlooked.'
Di fferentiating temporal bon e disea se fro m LCH ot itis ex tern a on ph ysical examination ca n be cha lle ngi ng . 15 Temporal bone disease is more often a localized process that invol ves mastoid swelling and the presence of pol yps or granulation tissue in the ear cana l. Soft-tissue infilt ration int o the externa l ea r ca na l" can cause conduct ive hearin g loss. Otorrhea and so me times otalgia ca n be present. Polyps tend to originate in the masto id and break throu gh the canal wall in a posterosuperior direction. Th e tympanic membrane, ossicles, and middl e ear are usu ally not invol ved. Wh en the middle ea r is involved, it is usually becau se of a secondary infection rath er than direct extension. 15.24.28 Otitis ex terna tend s to appea r in the presence of systemi c disease and is often assoc iate d with ex tens ive ski n disease invo lvi ng the scalp.15 On exa mination, there is often so muc h deb ris pre sent that it is difficult to determine whe ther the patien t has otiti s ex terna or pol yps. In such cases , it is best to take the pat ien t to the operating room for an examination under anesthesi a. Overall , otologic LCH rarely presents wit h otalgia or facial ner ve, inner ear, or oss ic ular chain invo lve ment. It is important to keep in mind that LCH may mimic other diseases such as cho les tea to ma . Th e only way to be certain is to obtai n a tissue diagn osis.
Surgical int erv enti on for otolog ic LCH has been associat ed with a high rate of co mplications .15Ma stoid disease can obsc ure normal facial ner ve landmarks, thereb y puttin g thi s structure at undue risk . In addition, middle ear Volume 83 , Number 5 surgery co uld lead to inner ea r invo lvem ent. " Agg ressive disea se ca n ex po se the sigmoid sinus and dur a," thereby increasing the risk of a du ral tear if operative man agem en t is se lec ted . Fis tula is also a freq ue ntly reported co mplication of surgery." :"
Irving et al fo und that the surg ical co mplica tion ra te was high and the rate of di sease co ntro l was low.15Of the 8 surgical patient s in their series who und erw ent so me form of mastoid ectomy, 2 develop ed a co mplete sensorine ura l hearing loss and 2 develop ed postau ricular fis tulae. All requ ired further treatm ent. On e patient ultimatel y died of multisystem di sease . Al so in that series , 17 patients with temporal bon e invol vement were treated conservative ly. Nonmedical interv ention in the se patients was limited to aur al polypectomy, plu s radiation therapy in I pati ent. Disease was co ntrolled in all cases, although I patient developed mild bilateral se nso rineura l hea rin g loss. Th e autho rs concluded that conse rvative treatment for oto logic LCH is superior to surgery .
Wh en surgery is chosen , the tran scanal approac h is often the most stra ightforward and least invasive me an s of obta ining a biop sy spec ime n. However, this approa ch may yie ld only superficial granula tion tissue . Furthermore, there has been at least one report of facia l ner ve injury during the tran scan al approach.' In that case, a prebiop sy CT wo uld like ly have shown eros ion of the facia l ner ve ca na l and alerted the surgeon to a potentiall y di splaced nerve . Whil e Irvin g et ails fo und otherwise , the tran smastoid approach may be a more reli able way of obtaining a definitive biop sy speci me n. Th e lesion is usu all y presen t on the temporal bon e surface and can be easily accessed. Lesion s limited to th e mastoid cortex ca n be treat ed with simple mastoid ectomy, but they hav e also been rep orted to heal on their own."
Otol ogic LCH usually respond s well to medical therapy . In the series by Irving et al , pati ents who receiv ed systemi c treatment ex perience d a resolution of their otitis ex ter na ." Th e autho rs found that mu stine drop s were an effec tive treatment for otitis, altho ug h care must be tak en whe n a tympani c membran e perforation is present beca use the dru g can theoreti call y da mage the inner ear. In patients wit h locali zed disease, researchers ha ve fo und that only 50 % res po nde d to stero id drop s while 100 % respond ed to mu stin e dro ps (20 mg/dl). " :" Some ce nte rs have used low-d ose radi ation both as an adj unctive treatment and as the so le treatm ent fo r temporal bo ne LCH Y ·33.34 By deli vering a low but therapeutic dose, co mplications such as radia tion ot itis can usuall y be avo ide d. It is imp ortant to keep in mind that regardless of treatm ent, more than 90% of unifocal osseous lesion s are cure d." :" Rad iati on therap y sho uld therefore be used judiciou sly and rarely in type I d isea se of the temporal bon e. Foll ow-up CT app roxim ately I year follow ing treatm ent has been recommend ed . In cases when there is erosion into the cranium, an intracranial soft-tissue mass may be visible on CT. In these situations, magnetic resonance imaging (MRI ) can help delineate the relationship between the lesion and delicate intracranial structures. The soft-tissue mass will appear hyperintense on T2-weighted MRI and will range from isointense to hypointense on Tl-weighted imaging. The mass will enhance with gadolinium and will often be associated with perilesional edema or inflammation."
Fernandez-Latorre et al reported a retrospective series of 14 LCH patients with temporal bone involvement from the radiologist' s perspecti ve." All but 2 of these patients had temporal bone disease at presentation. Patients were evaluated by CT both initially and during a follow-up that ranged from 2 to 14 years (mean: 5). Four patients had bilateral disease. Bony destruction was obvious on CT in all patients, and all but 2 had an associated soft-tissue mass on CT. In 2 patients, the mass was heterogenous. Although the authors did not specify any treatment methods in their report, they noted that the lesions resol ved in half of these patients. They also reported that patients with multisystem disease tended to have recurrent skull lesion s 348 that wer e more aggressive than the initi al temporal bone lesions. The se recurrent lesion s tended to involve the greater wing of the sphenoid bone. In addition, 4 of the 6 patients with multisystem disease developed diabetes insipidus. The authors noted that resolution is heralded on CT when the soft-tissue mass disappears. Fernandez-Latorre et al also observed that reossification tended to occur approximately 1 year later. Although Marioni et aP7 found that LCH rarely involved the squamous part of the temporal bone, Fernandez-Latorre et aP8found squamous lesions in 8 of their 14 patients.
According to Goldsmith et ai, LCH of the temporal bone is rarely limited to the petrous apex , although they did describe 2 such cases in their series." Nine of the 14 patients in the series by Fernandez-Latorre et al had middle ear lesions, and there was a relatively high rate of ossicular involvement (14.4%) .38 Skeletal x-rays play an important role at the time of diagnosis and in surveying bony involvement ofLCH. On x-ray, LCH lesions typically have a " shining" quality. They often show a beveled edge with sclerotic margins. The lesions may also appear to be well circumscribed. They may also have a punched-out appearance.v" although this finding is hardly exclusive to LCH.
On bone scintigraphy, lesions may take up tracer material uniformly or they may appear to have a low-uptake focus with a high-uptake rim . Howarth et al found that the sensitivity and specificity for detecting LCH lesions were 100 and 61%, respectively, on x-ray ; the corresponding figures for bone scintigraphy were 91 and 55%.40 This suggests that x-ray is the more appropriate method for evaluating and following LCH .
In conclusion, we recommend a minimalist approach that is limited to biopsy whenever possible. More research needs to be conducted so that we may better unde rstand the mechanisms of LCH and to help us predict when the disease will be benign and resolve on its own and when it will be aggressive and unremitting and require treatment.
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